Portugal Open For Business: Hovione increases the production of essential excipient for combating COVID-19
Portuguese pharmaceutical company Hovione has established a partnership with Ligand to significantly increase the production of Captisol®, an essential excipient for the production of the antiviral Veklury® (remdesivir), by Gilead Sciences. This antiviral is indicated for the treatment of infections by SARS-CoV-2, the virus that causes COVID-19.
Hovione is the only manufacturer of this essential excipient for the effectiveness of remdesivir, which is manufactured in its facilities in Portugal and Ireland. Hospitals and patients around the world rely on Hovione, which is mobilizing the company globally to ensure the supply of this component.
Hovione will produce per month the amount equivalent to what it used to produce in a year, having invested heavily in specialized equipment, in strengthening its teams, and in collaborating with competitors to increase its production capacity.
Portugal is a country open to business, which has adapted to COVID-19. Hovione is one of many examples of Portugal Open For Business.